We first examined the effect of bioactive recombinant human chemerin (huChem-157) (R&D Systems, 2324-CM-025) on ovarian cancer cell lines in standard adherent 2D culture conditions. This evidence concerns the gene RARRES2 and ovarian carcinoma.